Precision sniper for solid tumors: CAR-NK cell therapy.

Sisi Li, Jiajie Jing, Yueming Chen, Enjie Chi, Bingyan Wang, Ziwen Xie, Wenya Yang, Hongqiang Shen, Jianping Pan
{"title":"Precision sniper for solid tumors: CAR-NK cell therapy.","authors":"Sisi Li, Jiajie Jing, Yueming Chen, Enjie Chi, Bingyan Wang, Ziwen Xie, Wenya Yang, Hongqiang Shen, Jianping Pan","doi":"10.1007/s00262-025-04106-z","DOIUrl":null,"url":null,"abstract":"<p><p>Chimeric antigen receptor (CAR) represents a novel targeted therapy that uses genetic engineering to modify effector cells for precise tumor cell targeting. Chimeric antigen receptor-T (CAR-T) cell immunotherapy, which employs T cells as effectors, has demonstrated significant efficacy in treating hematologic malignancies. However, its efficacy against solid tumors remains inadequate and is accompanied by toxic side effects, including cytokine release syndrome, neurotoxicity and on-target/off-tumor effects. In contrast to T cells, natural killer (NK) cells exhibit a broader source range and can non-specifically lyse tumor cells. Moreover, it can also reduce toxicity and side effects to some extent. This review comprehensively examines recent research progress on CAR-NK therapy for solid tumors, encompassing both in vivo and in vitro studies, with a focus on CAR-NK cell design and production methods. Drawing upon laboratory and clinical evidence, this review summarizes the current challenges and side effects associated with CAR-NK technology.</p>","PeriodicalId":520581,"journal":{"name":"Cancer immunology, immunotherapy : CII","volume":"74 9","pages":"275"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer immunology, immunotherapy : CII","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00262-025-04106-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Chimeric antigen receptor (CAR) represents a novel targeted therapy that uses genetic engineering to modify effector cells for precise tumor cell targeting. Chimeric antigen receptor-T (CAR-T) cell immunotherapy, which employs T cells as effectors, has demonstrated significant efficacy in treating hematologic malignancies. However, its efficacy against solid tumors remains inadequate and is accompanied by toxic side effects, including cytokine release syndrome, neurotoxicity and on-target/off-tumor effects. In contrast to T cells, natural killer (NK) cells exhibit a broader source range and can non-specifically lyse tumor cells. Moreover, it can also reduce toxicity and side effects to some extent. This review comprehensively examines recent research progress on CAR-NK therapy for solid tumors, encompassing both in vivo and in vitro studies, with a focus on CAR-NK cell design and production methods. Drawing upon laboratory and clinical evidence, this review summarizes the current challenges and side effects associated with CAR-NK technology.

实体瘤的精确狙击:CAR-NK细胞疗法。
嵌合抗原受体(CAR)是一种利用基因工程修饰效应细胞以精确靶向肿瘤细胞的新型靶向治疗方法。嵌合抗原受体-T (CAR-T)细胞免疫疗法,利用T细胞作为效应器,已经证明了治疗血液系统恶性肿瘤的显着疗效。然而,其对实体瘤的疗效仍然不足,并伴有毒副作用,包括细胞因子释放综合征、神经毒性和靶/非肿瘤效应。与T细胞相比,自然杀伤(NK)细胞表现出更广泛的来源范围,可以非特异性地溶解肿瘤细胞。此外,它还可以在一定程度上减少毒副作用。本文综述了CAR-NK治疗实体瘤的最新研究进展,包括体内和体外研究,重点是CAR-NK细胞的设计和生产方法。根据实验室和临床证据,本文总结了CAR-NK技术目前面临的挑战和副作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信